Lilly Asia Ventures Fund VI

Lilly Asia Ventures

cb Email

Status

ACTIVE

Global HQ

Shanghai, China

Countries of investment

China
United States
Singapore
Japan
South Korea
India
Australia

Investment stages

Seed
Series A
Series B
Series C
Growth

Industries

Biopharmaceuticals
Therapeutics
Medical Devices
Diagnostics
Life Sciences
Healthcare

About
Lilly Asia Ventures is a Shanghai-based biomedical venture capital firm originated in 2008 as a corporate venture subsidiary of Eli Lilly, spun off as an independent investment management company in 2011. With approximately $4.5 billion in AUM and offices in Shanghai, Hong Kong, and Palo Alto, LAV invests in biopharmaceuticals, medical technologies, and diagnostics from seed through publicly traded stages across Asia and the United States.

Min check size: $5M
Max check size: $30M
Fund size: Unlock
NPS: Unlock

Investment Thesis

Lilly Asia Ventures focuses on becoming the trusted partner for exceptional entrepreneurs seeking smart capital to build great companies developing breakthrough products that treat diseases and improve human health. The thesis leverages deep biomedical resources and global connections.

Lead investor: Unlock
Co Invest: Unlock
Number of exits: Unlock
Preferred contact method: Unlock

Manager's Experience

Lilly Asia Ventures is led by Founder and Managing Partner Yi Shi, with a team of over 50 distinguished professionals across science, medicine, investment, and operations. The firm originated in 2008 as a corporate venture subsidiary of Eli Lilly and spun off as an independent investment management company in 2011. The partners bring deep expertise in preclinical and clinical development, regulatory know-how, and market insights, supported by a large network of scientific advisors and a portfolio that includes 1 unicorn and IPOs such as Alector, ArriVent, and Insilico.